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INTRODUCTION
Protein biomarker discovery 
requires multidisciplinary strategies 
that incorporate intelligent sample 
collection, processing, data acqui-
sition, and analysis (see Reference 2). 
Protein identification has historically 
been accomplished by Edman degra-
dation. Although an arguably powerful 
technology, it suffers both in terms of 
throughput and scope, as proteins can 
only be sequenced consecutively and 
only after appreciable purification. 
Furthermore, even if these criteria are 
fulfilled, this technology falls short, 
in that it provides no facile translation 
to routine protein assay development. 
Improvements in biomarker assays 
have all relied on the development 
and use of high affinity reagents 
(i.e., antibodies). The development 
of modern separations coupled with 
advanced mass spectrometry (MS) 
has ushered in a new paradigm in the 
throughput and scope with which 
proteins can be identified and charac-
terized. These proteomic-scale capabil-
ities now enable thousands of proteins 
to be identified from complex mixtures 
(1). Indeed, no other technology 
parallels the capability of MS in the 
identification of proteins from complex 
proteomic samples, such as serum, 
plasma, urine, or cerebrospinal fluid 
(CSF). It is for these reasons that 
conventional wisdom suggests that 
through application of these new tools, 
novel and specific disease biomarkers 
will be identified. Accordingly, the 
recent past has seen an exponential rise 
in data acquisition (i.e., MS) and data 
analysis (i.e., computer hardware and 
software) capabilities, while it may be 
argued that commensurate advances in 
sample collection and processing have 
lagged. The increasing power of MS 
and bioinformatic tools often results 
in experimental designs that are overly 
dependent on technology and suffer 
from lack of imaginative sample prepa-
ration. As shown in Figure 1, there is 
often an inverse relationship between 
the complexity of sample preparation 
and the amount of data acquired or 
the sophistication of the bioinformatic 
analysis. Simply put, minimal sample 
preparation prior to MS analysis will 
require more data acquisition and more 
sophisticated bioinformatic analysis. 
There is, however, a direct correlation 
between the amount of data acquired 
and the sophistication of the bioinfor-
matic analysis.
ANALYTICAL SAMPLING OF 
BIOFLUIDS
In the simplest sense, the goal of 
protein biomarker discovery is to 
identify a protein or panel of proteins 
that distinguish patients afflicted 
with a particular disease from healthy 
individuals (2). While the premise 
seems simple enough, achieving 
this goal has not been a trivial 
pursuit. Ideally, such a biomarker or 
biomarkers would be assayable in 
biological samples obtained through 
minimal invasion. Biofluids such 
as urine, serum, and plasma readily 
fulfill such criteria and are routinely 
collected during physical examina-
tions. Unfortunately, these biofluids 
represent an extremely difficult matrix 
to characterize, even by the most 
advanced MS technologies. These 
difficulties are clear if one considers 
the physiological and analytical 
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challenges in discovering, for example, 
a tumor-specific protein biomarker in 
serum. Assume that a population of 
tumor cells secretes an aberrant protein 
into the circulatory system. The blood, 
collected from a vein at the inner elbow 
and from which the serum sample 
is prepared, is derived from a 7.5-L 
circulatory system that encompasses 
approximately 100,000 km of veins, 
arteries, and capillaries. While the 
local concentration of the biomarker 
may be high in the microenvironment 
of the tumor, its travels take it through 
thousands of kilometers of biological 
highways until it reaches the point 
of extraction (i.e., inner elbow). This 
journey will have many confounding 
effects that present several analytical 
challenges to its facile detection, the 
most obvious of which is dilution. The 
high concentration of the biomarker 
within the vicinity of the tumor 
will be dramatically decreased as it 
moves within the circulatory system. 
Since the activity level of proteases 
in blood is high, the biomarker may 
also be digested into a variety of 
different fragments prior to collection. 
Therefore the primary sequence, and 
potentially the functional significance, 
of the biomarker can radically change 
between the point of entry into the 
circulation system and collection.
Probably the most challenging 
aspect of discovering biomarkers in 
biofluids such as serum and plasma is 
their proteomic complexity (3). While 
the exact number of proteins is not 
known, it has been estimated that has 
many as 105–106 different species may 
be constituents in the blood proteome. 
Adding to that complexity, the blood 
proteome is in a persistent state of 
flux, with materials being exchanged 
with healthy cells and proteins being 
released from necrotic and apoptotic 
cells. Furthermore, this complexity 
is not simply a function of the sheer 
numbers of proteins, but also the 
dynamic range of their concentrations 
estimated conservatively at minimally 
ten orders of magnitude (4).
With these factors to consider, 
obviously the ability to comprehen-
sively characterize these biofluid 
proteomes is a critical first step in the 
hope of identifying clinically signif-
icant biomarkers. In the recent past, 
there have been a number of studies 
utilizing different separation technol-
ogies followed by MS protein identifi-
cation to characterize these proteomes 
(5). The two primary separation 
methods for obtaining comprehensive 
proteome coverage have been two-
dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) and multi-
dimensional liquid chromatography 
(LC) (i.e., strong cation exchange 
LC followed by reversed-phase LC). 
Research conducted at Large Scale 
Biology Corporation (LSBC; Vacaville, 
CA, USA) has been instrumental in 
highlighting the utility of 2D-PAGE/
MS analyses in biofluid proteomics. 
Studies conducted at LSBC demon-
strated the resolution of over 1400 
and 3700 distinct protein spots on 
2D-PAGE gels from urine and serum 
samples, respectively, resulting in the 
respective identification of 150 and 325 
unique proteins (6,7). Investigations 
using multidimensional LC coupled 
to MS analysis have typically resulted 
in the identification of 1500–2000 
proteins in serum or plasma and 100–
250 proteins in urine (8,9). Although it 
might be argued that 2D-PAGE results 
in fewer protein identifications, the 
upshot is that it provides quantitative 
information in comparative analyses 
through the comparison of stained 
protein spot intensities and infor-
mation related to protein isoforms 
and posttranslational modifications. 
Multidimensional fractionation allows 
more protein identifications but 
suffers from less rigorous quantitative 
comparisons that are based typically 
on the number of peptides observed 
and/or their raw ion current for a given 
protein. While the numbers of proteins 
identified using either method do not 
approach the expected complexity 
of the given biofluid, they do provide 
orders of magnitude more coverage 
and information than available prior 
to the proteome era and warrant the 
use of these technologies in biomarker 
discovery.
In many ways, biomarker discovery 
using such technologies is a case of 
the proverbial needle-in-the-haystack 
expedition without knowing what the 
haystack or the needle looks like. The 
hope is that the data reveal a handful 
of proteins that distinguish disease and 
fulfill the necessary criteria to move 
to a validation stage using expanded 
clinical cohorts. There has been a 
tremendous amount of resources, both 
in terms of time and money, devoted to 
global biofluid analysis for biomarker 
discovery. While there have been many 
potentially useful biomarkers put 
forth in the literature, there have been 
none that have been validated to meet 
Food and Drug Administration (FDA) 
requirements. Does this mean the 
leveraging of MS and bioinformatics 
to analyze complex biofluid samples 
has been a waste of time? Absolutely 
not! The analytical advances made in 
the development of instrumentation 
with greater acquisition speed, sensi-
tivity, dynamic range, and resolution, 
as well as bioinformatic tools that 
more accurately identify proteins, 
have allowed a greater understanding 
of the proteome content of many 
biofluids. We are only now beginning 
to understand changes in the proteomes 
common to many disease conditions 
and in a sense recognizing just what the 
haystack looks like.
SOURCES OF CLINICAL 
SAMPLES
An ideal biomarker would be found 
in a biological specimen that can be 
obtained noninvasively and, in the case 
of cancer, be as directly proximal to the 
Figure 1. Graphical representation of the de-
pendency of the mass spectral data acquisition 
and bioinformatic effort based on the level of 
experimental focus in proteomic investiga-
tions. As illustrated, increased experimental fo-
cus results in a corresponding decrease in both 
mass spectrometry (MS) data acquisition and 
bioinformatic effort.
Vol. 40, No. 6 (2006) BioTechniques 801
underlying tumorigenesis as possible 
to endow high levels of specificity and 
sensitivity to the disease. Biofluids 
such as serum, plasma, urine, and CSF 
have been the predominant choice for 
biomarker discovery. One obvious 
reason is their accessibility; acquiring 
tumor biopsies from patients is invasive, 
costly, and impractical. Another reason 
arises from a forward thinking vision for 
development of routine clinical assays. 
Unfortunately, the sheer complexity 
of these biofluids prevents direct 
association of a protein identified from a 
proteomic study to its site of origination. 
Fortunately, recent developments in 
utilizing new techniques that enable 
sampling of material closer to the site 
of interest may provide more directed 
routes to the identification of biomarkers 
suitable for clinical validation.
Formalin-Fixed Paraffin-Embedded 
Tissues
To correlate the biomarker-tumor 
connection, tumor biopsies have to be 
performed and other biochemical or 
imaging methods, such as immunohis-
tochemistry, also need to be performed 
to validate the site of origination of a 
given protein biomarker. The extraction 
of tumor material either surgically or 
through a needle biopsy, however, is 
highly invasive, and the costs (both in 
terms of time and money) of obtaining 
sizable cohorts of samples from willing 
donors makes such studies almost 
impractical for discovery-driven 
biomarker research. Fortunately, there 
is a vast archive of tumors in the form 
of formalin-fixed paraffin-embedded 
(FFPE) tissues. While these tissues 
have been routinely used for immuno-
histochemistry, in situ hybridization 
studies, and more recently, in array-
based genomic and transcriptomic 
analyses, their utility in discovery-
driven proteomics has been essentially 
nonexistent. The general belief has 
been that the fixation procedure results 
in formaldehyde-induced inter- and 
intramolecular covalent cross-links 
that renders proteins intractable to 
downstream fractionation, digestion, 
and MS analysis (10).
Recently, three studies have been 
reported that demonstrate the potential 
of using FFPE samples in discovery-
driven proteomics (11–13). While slight 
overall differences exist, two of these 
combined enzymatic digestion with 
liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis 
of proteins extracted from FFPE 
samples. In one study, this capability 
was demonstrated through fixation 
of a confluent culture of follicular B 
cell lymphoma cells (SUDHL-4) (11). 
Lysis buffer was added to 10 sections 
cut from the fixed sample to extract the 
protein complement of the cells, which 
was subsequently digested into peptides 
using either trypsin or glutamic-C 
endopeptidase (Glu-C). Analysis of the 
samples by LC-MS/MS resulted in the 
identification of 324 proteins from two 
or more unique peptides. The identifi-
cation of important signaling proteins 
such as Raf-B, JAK1, STAT1, and 
protein kinase C (PKC) was confirmed 
by immunoblot analysis.
In a clinically relevant application, 
another study combined the use of 
laser capture microdissection with 
proteomic analysis to investigate 
prostate cancer (PCa) and benign 
prostatic hyperplasia (BPH) from 
cells captured from archived FFPE 
prostate tissue (12). Tryptic peptides 
were extracted from each of the histo-
logically distinct cells and separately 
analyzed by LC-MS/MS, as illustrated 
in Figure 2. In total, 1156 and 702 
unique proteins were identified from 
the PCa and BPH FFPE tissue extracts, 
respectively. Differences in protein 
abundance from the PCa and BPH cells 
were determined by comparing the 
number of unique peptides identified 
from a specific protein. A variety 
of prostate-related proteins, such as 
prostatic acid phosphatase (PAP), Raf 
kinase inhibitor protein (RKIP), and 
most notably prostate-specific antigen 
(PSA), were identified in both sample 
types by multiple peptides (Table 1). In 
contrast, growth differentiation factor 
15 (GDF-15) was only identified by 
four unique peptides in PCa cells. This 
result is in agreement with a previous 
study that showed an up-regulation of 
GDF-15 in PCa cells compared with 
high-grade prostatic intraepithelial 
neoplasia (hPIN) cells (14).
These studies also evaluated the 
effect of FFPE processing versus more 
commonly used fresh/frozen cells and 
tissues, by comparing the proteomes 
from each sample source. Comparison 
of FFPE and fresh SUDHL-4 cells 
resulted in the identification of 324 
and 512 proteins, respectively (11), 
while a comparison of 30,000 cells 
microdissected from FFPE and frozen 
mouse liver resulted in similar numbers 
of protein identifications from each 
sample (approximately 88% as many 
proteins could be identified from the 
FFPE sections as from frozen sections) 
(12). Besides the number of peptides 
and proteins identified, what was 
particularly encouraging in the analysis 
Figure 2. Characterization of formalin-fixed paraffin-embedded (FFPE) prostate tissue by liq-
uid chromatography-tandem mass spectrometry (LC-MS/MS). (A) In this study (Reference 12), 
cells from regions of prostate cancer (PCa), stroma, and benign prostatic hyperplasia (BPH) were laser 
capture microdissected from the tissue. Peptides were extracted from each cell type and analyzed by 
LC-MS/MS. 
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of the FFPE and frozen tissue was the 
similarity in the base-peak chromato-
grams (BPC) and the tandem mass 
spectra obtained from both samples. 
The similarities in the BPC and the 
tandem mass spectra suggest that the 
population of proteins extracted from 
each sample type is comparable.
Taken together, these observations 
suggest that the vast archive of FFPE 
tissues, a heretofore unexplored clinical 
sample source, may provide a valuable 
new avenue for biomarker discovery. 
This new accessibility of FFPE tissues 
to proteomic research could catalyze a 
shift in the manner in which candidate 
biomarkers are identified for validation 
in biofluids (e.g., in cancer research). 
An alternate option to the present 
paradigm of analyzing biofluids to 
identify differentially abundant protein 
biomarkers related to disease may 
be to first analyze clinical cohorts of 
FFPE tumor tissues, rendering a subset 
of proteins proximal to the disease 
mechanism that can be validated via 
assay in the appropriate biofluid in 
expanded clinical cohorts.
This new paradigm has many 
potential advantages over standard 
biomarker identification/evaluation 
protocols. First, potential biomarkers 
discovered using MS approaches could 
be validated by immunohistochem-
istry within a section cut from the 
same tumor. Second, if the presence 
of the tumor-related proteins can be 
validated in a corresponding biofluid, 
the confidence in linking the origin 
of the proteins to the diseased tissue 
is greatly increased than if they were 
simply identifying the proteomic 
survey of the biofluid alone. While 
not discussed in great depth, a major 
problem in attempting to find disease-
specific biomarkers in serum or plasma 
is that acute phase and inflammatory 
response proteins are typically up-
regulated under many different condi-
tions, adding to the complexity of the 
biofluid, but having limited utility for 
diagnostic purposes. Direct analysis 
of the tumor should also ameliorate 
the background differences associated 
with these proteins that are commonly 
observed in the analysis of serum or 
plasma from disease-stricken patients.
Organ Perfusion
A clever strategy for eliminating 
the complexity of these biofluids and 
permitting the identification of proteins 
that may be shed or secreted from the 
diseased tissue was recently described by 
Koomen et al. (15). In this study, isolated 
beating hearts were dissected from rats 
and immediately perfused for approxi-
mately 5 min to remove blood from the 
organs. The hearts were then subjected 
to ischemic conditions and reperfused. 
The effluent from this perfusion was 
collected in various fractions that were 
subsequently analyzed by LC-MS/MS 
for protein identification and sodium 
dodecyl sulfate PAGE (SDS-PAGE) 
to verify the removal of background 
serum/plasma proteins. The SDS-PAGE 
results showed a dramatic decrease (i.e., 
at least 90%) in the level of albumin in 
the perfused samples collected after 
blood had been removed from the heart. 
Analysis of the perfusion effluent by 
LC-MS/MS resulted in the identification 
of 342 proteins. Approximately one-
third of the proteins were cytoplasmic in 
origin, while another third were 
common resident serum/plasma 
proteins. Several biomarkers 
for myocardial injury such 
aspartate aminotransferase, 
creatine kinase MB, cardiac 
troponin I, cardiac troponin T, 
glycogen phosphorylase, and 
heart fatty acid binding protein 
(FABP) were identified in the 
effluent. Other potentially 
valuable markers of myocardial 
ischemia were also identified 
such as myotrophin, neuropro-
tective protein DJ-1, atriopep-
tigen, which is the precursor for 
atrionatriuretic peptides, and the AMP 
phosphoramidate-hydrolyzing enzyme 
HINT1.
Obviously this technology has some 
drawbacks in application to human 
patients, primarily in the ability to 
acquire samples as well as the cellular 
heterogeneity of organ systems. 
Accordingly, the investigators proposed 
some intriguing applications of this 
sampling technology particularly in the 
analysis of human xenograft tumors 
in encapsulated organs of athymic 
or immunodeficient mice (15). This 
technique should allow tumor-specific 
(human) and host response (mouse) 
protein biomarkers to be easily discrim-
inated.
Functional Proteomic Assays
While not applicable to every type 
of study, using sample preparation 
methods to target a specific functional 
characteristic can often facilitate the 
discovery of a biomarker(s). These 
directed studies rely heavily on sample 
preparation techniques but do not 
require excessive MS data acquisition 
nor the need to burden the bioinformatic 
analysis to find the desired compounds 
among a complicated matrix. For 
instance, Dr. Benjamin Cravatt and 
coworkers have been leaders in 
developing activity-based protein 
profiling (ABPP) for the discovery of 
functional states specific to tumors 
(16). This technology uses chemical 
probes directed toward the active 
sites of specific classes of enzymes 
to detect functional changes in entire 
proteome samples. Recently this group 
teamed up with Dr. John Yates’ group 
to complement their functional assay 
capabilities with MS identification of 
the enzymes that were detected.
In one such application, this effort 
used fluorophosphonate (FP)-based 
ABPP probes that target serine hydro-
lases, a diverse class of enzymes that 
have been implicated in cancer (17). In 
the first phase of the study, rhodamine-
tagged FP-ABPP probes were added 
to 12 μg protein obtained from homog-
enized breast tumor tissue sections 
and then analyzed by SDS-PAGE with 
fluorescence detection, as shown in 
Figure 3A. The gel image revealed the 
profile of changes in serine hydrolase 
Table 1. Total Number of Peptides Identified
Protein PCa BPH Stroma
PSA 10 16 1
PEBP 12 7 3
PAP 31 28 0
GDF-15 4 0 0
Comparative analysis of the proteomes showed that pro-
teins such as prostate-specific antigen (PSA), prostatic 
acid phosphatase (PAP), and phosphatidylethanolamine 
binding protein (PEBP) were highly represented within both 
prostate cancer (PCa) and benign prostatic hyperplasia 
(BPH) cells, based on total peptide count. Growth-differen-
tiation factor 15 (GDF-15), however, was observed exclu-
sively with PCa cells.
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activity across different breast tumors. 
While the image demonstrated different 
activity profiles from different tumors, 
direct identification of the enzymes 
linked to these changes was not possible 
using this analytical platform.
To redress this deficiency, they 
employed a biotinylated FP-ABPP probe 
(instead of rhodamine-tag) as shown in 
Figure 3B. The probe-labeled proteins 
were enriched using avidin-conjugated 
beads. After on-bead trypsin digestion, 
the peptide mixture was analyzed by 
multidimensional LC-MS/MS. Over 50 
serine hydrolases were identified in the 
tumor proteomes using the biotin-FP 
ABPP probe. Only a few of the same 
activities were observed in the control 
reactions in which the probe was not 
added to the proteome sample. These 
enzymes included proteases, lipases, 
esterases, several proteasome subunits, 
and at least 15 uncharacterized hydro-
lases.
For quantitation, the spectral count 
(e.g., number of peptide identifications 
by MS/MS) for each hydrolase was 
averaged for the two different breast 
cancer samples. Several enzymes were 
identified that had at least a 3-fold 
change in activity among the breast 
cancer specimens. For example, fibro-
blast activation protein, KIAA1363 and 
platelet-activating factor acetylhydrolase 
2 were elevated in estrogen receptor/
progesterone receptor double negative 
[i.e., ER(-)/PR(-)] tumors compared 
with either ER(+)/PR(+) tumors or 
normal breast tissue. Other enzyme 
activities such as thrombin, dipeptidyl-
peptidase IV, and hormone-sensitive 
lipase, however, were found to be higher 
in normal breast tissue. While this study 
focused on the identification of changes 
in serine hydrolase activity, a number of 
functional probes are presently available 
for hypothesis-driven analyses of 
functional changes in tumor cells.
Cell-Based Assays
Cell-based assays are widely used in 
biological discovery (18); however, their 
combination with MS for biomarker 
discovery has been limited. In general, 
cell-based assays are used to determine 
the effect of a known compound on 
cells in culture or to attempt to find 
novel compounds within extracts that 
produce an effect. Unfortunately, there 
has not been much research showing a 
combination of cell-based assays and 
MS to discover biomarkers in biofluids. 
An excellent example of combining 
a cell-based assay with multidimen-
sional fractionation and MS analysis 
was demonstrated by the discovery of 
a biomarker for interstitial cystitis (IC) 
(19). Interstitial cystitis (which affects 
approximately one million Americans) is 
a chronic, debilitating, bladder disorder 
that results in the thinning of the bladder 
epithelial cell lining (20). This disorder 
is typically diagnosed only by exclusion 
of other maladies followed by a bladder 
biopsy under general anesthesia. It was 
discovered in the 1990s that the urine of 
patients with IC contained a factor that 
inhibited bladder epithelial cell growth 
in culture. This antiproliferative factor 
(APF) was also found in the supernatant 
of epithelial cells in culture explanted 
from the bladders of IC patients, but not 
from healthy individuals (20). The true 
molecular nature (e.g., identity) of APF 
was not discovered, however, until 2004 
(19).
To discover the identity of APF, 
the groups involved used several 
chromatographic steps and a cell-
based assay to track APF through the 
various collected fractions, scored by 
measuring [3H]-thymidine incorpo-
ration into cultured bladder epithelial 
cells (an indicator of inhibition of cell 
proliferation) as illustrated in Figure 
4 (19). The fraction possessing the 
APF activity was graduated through 
the various chromatographic steps to 
increase its fold-enrichment, which was 
subsequently analyzed by LC-MS/MS. 
After a series of validation steps that 
included comparison of synthetically 
generated molecules with structures 
approximating the isolated molecule, 
APF was validated as a nine-residue 
sialoglycopeptide. Subsequent clinical 
validation demonstrated the unique 
nature of APF in that the transcript 
that gives rise to this peptide is solely 
present in the urine of patients with IC 
and not in that obtained from healthy-
matched controls.
Considering the structure of APF, 
it is highly unlikely that it could have 
been identified in a global analysis 
comparing urine from IC and healthy 
patients using conventional proteomic 
strategies. Indeed, most global studies 
Figure 3. Combination of activity-based protein profiling (ABPP) and mass spectrometry (MS)-
based proteomic profiling to identify specific activities within complex human samples. (A) A rho-
damine (Rh)-tagged ABPP probe is used to isolate species that contribute a specific enzymatic activity 
from a proteome. The isolated proteins are then resolved by one-dimensional electrophoresis to provide 
enzyme activity signatures. (B) In the second phase, the same ABPP probe tagged with biotin (B) is then 
used in combination with avidin chromatography to extract the proteins giving rise to the specific activ-
ity. The extracted proteins are tryptically digested and analyzed by multidimensional liquid chromatog-
raphy-MS, for identification and to estimate their respective levels. m/z, mass-to-charge ratio.
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focus on comparing quantitative 
changes in unmodified, tryptic peptides 
derived after proteome digestion. The 
very nature of APF, namely a glyco-
sylated, nontryptic peptide, would have 
obviated its identification, particularly 
when one considers the current guide-
lines being established in the proteomic 
community (www.mcponline.org/misc/
ParisReport.shtml). The discovery of 
the structure of APF required a large 
effort in sample preparation, but in turn 
required a single LC-MS/MS exper-
iment. The bioinformatic burden on the 
structure determination was accord-
ingly slight as well, as the tandem 
mass spectrum was interpreted de 
novo. Validation of the final structure 
also required minimal MS and bioin-
formatics support, but instead relied 
on techniques such as lectin chroma-
tography and synthetic chemistry. 
Ultimately the successful identification 
of this important biomarker for IC 
depended on the cell-based assay to 
pinpoint the activity of APF in various 
chromatography fractions. The entire 
process is analogous to separating “the 
needle from the haystack” prior to MS 
identification.
CONCLUSIONS
Proteomics currently exists in a 
discovery and survey era where MS, 
and its affiliate technologies, is focused 
on identification of candidate novel, 
biofluid-based biomarkers for various 
disorders. As shown through the 
variety of examples presented in this 
review, the challenges are immense, 
and there is often a trade-off between 
the amount of effort placed in sample 
preparation, the amount of MS data 
acquisition, and the need for bioinfor-
matics analysis. While the investments 
in these technologies have yet to yield 
large numbers of validated biomarkers, 
they have allowed researchers to begin 
analyzing complex samples in ways 
not possible as recently as 5 years ago. 
The past couple of years have been 
witness to new and imaginative ways to 
analyze clinical samples that target the 
site of the disorder and may eventually 
yield validatable biomarkers with high 
sensitivity and specificity.
As the analytical technology 
applied to proteomic analysis of 
complex biological samples increases 
in sensitivity, there is an increasing 
burden placed on the standardization 
of sample collection and handling. 
Artifacts arising from nonspecific 
proteolysis and protein degradation are 
likely to be quite variable depending 
on details such as sampling-handling 
parameters. A recent study showing the 
ability to classify solid tumors based 
on the signature peptides produced by 
the action of exopeptidases postex-
traction (21), underscores the need 
for consistent sample handling prior 
to analysis. Even for samples such as 
FFPE tissues, the variability introduced 
by formalin-fixation time and length 
of storage are not yet well understood. 
The effects (and potential artifacts) 
introduced by sample acquisition, 
storage, and processing will need to 
be measured in a systematic manner 
within a well-controlled study.
Although the application of MS 
for protein biomarker investigations is 
arguably the most powerful discovery-
driven methodology, the ultimate goal is 
to mobilize such discoveries to routine 
clinical application for in vitro diagnostic 
assays. Although these MS-based appli-
cations exist, namely the powerful assay 
Figure 4. Incorporation of chromatography and a cell-based assay to aid in the identification of 
the antiproliferative factor (APF) for interstitial cystitis (IC). Fractions were collected during each 
chromatographic separation and tested for their ability to inhibit bladder epithelial cell proliferation in 
vitro. Fractions containing APF activity were then promoted to the next chromatographic step until the 
enrichment of APF was high enough to enable it to be identified by mass spectrometry and de novo se-
quencing. m/z, mass-to-charge ratio.
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to screen newborns for inborn errors 
of metabolism (22), there are many 
hurdles to overcome in the translation 
of MS technology to the development 
of routine clinical diagnostic assays 
of protein biomarkers from complex 
matrices. In perhaps a more idealized 
biomarker developmental workflow, high 
affinity reagents, such as monoclonal 
antibodies, would be generated against 
lead biomarkers forthcoming from 
MS-based discovery-driven investiga-
tions. These reagents have a long and 
rigorously validated history of use in 
in vitro diagnostic applications and in 
large part are likely to contribute to a 
shorter trajectory to clinical adoption of 
newly discovered biomarkers, especially 
when the validation and regulatory due 
diligence that underpin such transla-
tions is considered. The production of 
an antibody with high affinity and speci-
ficity for an antigen, however, is never a 
guarantee. It will not be surprising if MS 
begins to play a larger role in biomarker 
validation as the analytical attributes (i.e., 
sensitivity, resolution, direct detection, 
etc.) that make it the premier technology 
for proteome characterization also 
enable it to interrogate specific species in 
complex mixtures (23).
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